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Parkinson’s disease is a debilitating neurodegenerative disorder, and its molecular etiopathogenesis remains poorly understood.
The discovery of monogenic forms has significantly advanced our understanding of the molecular mechanisms underlying PD,
as it allows generation of cellular and animal models carrying the mutant gene to define pathological pathways. Mutations in
leucine-rich repeat kinase 2 (LRRK2) cause dominantly inherited PD, and variations increase risk, indicating that LRRK2 is an
important player in both genetic and sporadic forms of the disease. G2019S, the most prominent pathogenic mutation, maps to
the kinase domain and enhances enzymatic activity of LRRK2, which in turn seems to correlate with cytotoxicity. Since kinases
are druggable targets, this has raised great hopes that disease-modifying therapies may be developed around modifying LRRK2
enzymatic activity. Apart from cytotoxicity, changes in autophagy have been consistently reported in the context of G2019S mutant
LRRK2. Here, we will discuss current knowledge about mechanism(s) by which mutant LRRK2 may regulate autophagy, which
highlights additional putative therapeutic targets.
1. Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder with symptoms including tremor, rigidity, and
postural instability [1]. Autosomal-dominant mutations in
leucine-rich repeat kinase 2 (LRRK2) comprise the most
common monogenic form of PD [2–5]. LRRK2-associated
PD is symptomatically and neurochemically largely indis-
tinguishable from sporadic PD cases [6], even though the
reported pleomorphic pathology of mutant LRRK2 carriers
diﬀers from the rather classical α-synuclein pathology asso-
ciated with sporadic PD. Variations in LRRK2 have further
been reported to increase risk for sporadic PD [7–9], which
implicates LRRK2 in both sporadic and familial forms of
the disease. The big advantage of studying the function
of a mutated gene product as compared to a sporadic
disease is that one can generate cellular and animal models
carrying the mutant gene to define pathological pathways.
In conjunction with the described enzymatic activity of
LRRK2 which may be targeted by select kinase inhibitors
[10, 11], this has propelled the protein into the limelight
of PD research worldwide. However, to develop disease-
modifying or neuroprotective therapies around LRRK2, a
clear understanding of its normal and pathological func-
tion(s) is required. A link between LRRK2 and aberrant
macroautophagy has been consistently observed, and here we
review our current knowledge of LRRK2’s role in autophagy
and lysosomal homeostasis with implications for cell demise
in PD.
2. LRRK2 Structure and Cellular Localization
LRRK2 is a large multidomain protein belonging to the
ROCO family of proteins which are characterized by the
presence of leucine-rich repeats, a Ras of complex (ROC)
GTPase domain, a C terminal of ROC (COR) linker region,
and a kinase domain [12]. Among the many putative
pathogenic variants identified to date, six missense muta-
tions in LRRK2 have been clearly shown to segregate
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Figure 1: Domain structure and PD mutations of LRRK2. The central region of LRRK2 contains a GTPase domain also called (ROC),
a C-terminal of ROC (COR) domain of unknown function, and a kinase domain, flanked on either side by protein-protein interaction
domains including an ankyrin repeat domain (ANK), leucine-rich repeats (LRR) and aWD40 domain (WD40). Clearly causative pathogenic
mutations are indicated and are clustered around the catalytic domains of LRRK2. Only the G2019S mutation consistently augments kinase
activity.
with disease, and thus represent authentic disease-causing
variants [13]. Importantly, these mutations all map to the
central region comprised of the catalytic domains, indicating
that a change in enzymatic activity (either GTPase or kinase)
mediates the pathogenic eﬀect(s) of LRRK2 (Figure 1). The
G2019S mutation within the kinase domain (Figure 1) is
the most frequent pathogenic LRRK2 mutation, having been
identified in up to about 40% of familial PD cases dependent
on ethnicity, and also detected in apparent sporadic PD cases
[4, 5, 7–9]. This mutation has been consistently shown to
augment catalytic activity [14], even though the inherent
kinase activity of LRRK2 is very low. This may be, at least in
part, due to the lack of currently identified and reproducible
genuine kinase substrates. LRRK2 kinase is active towards
itself [14], and autophosphorylation may represent a phys-
iological readout. The eﬀect of other pathogenic mutations
on kinase activity is less clear. Intriguingly, a recent study
indicates that the G2385R risk variant causes a partial loss
of kinase activity, highlighting the possibility that both too
much or too little LRRK2 kinase activity may be detrimental
[15]. Mutations in the ROC and COR domain cause a
decrease in GTPase, without gross changes in kinase activity
[16, 17], suggesting that the GTPase activity may comprise
the genuine physiological readout of LRRK2, which may
be further modulated by kinase activity [11]. Finally, apart
from the catalytic central domains, LRRK2 contains vari-
ous protein-protein interaction domains including LRRK2-
specific, ankyrin, and leucine-rich repeat motifs at the N-
terminus, and WD40 repeats near the C-terminus of the
protein (Figure 1). The existence of these domains indicates
the possibility that it may act as a protein scaﬀold for the
assembly of protein complexes [18]. Indeed, LRRK2 has
been reported to interact with a whole array of proteins
and may form distinct protein complexes in a cell-type
or subcellular compartment-specific manner [19]. In this
context, the enzymatic activities of LRRK2 may serve to
change the aﬃnity and/or composition of such complexes.
Alternatively, a change in enzymatic activity may be the result
of a change in protein complex interaction(s). Consistent
with the latter possibility, LRRK2 has been reported to exist
as a dimer, with dimerization enhancing kinase activity and
causing relocalization to intracellular membranes [20–23],
even though this has been disputed [24]. In either case, apart
from being cytosolic, overexpressed, as well as endogenous,
LRRK2 has been reported to localize to specific membrane
subdomains including endolysosomal structures in neuronal
and non-neuronal cells [25–27]. There, it may interact with
and/or regulate distinct protein complexes. Such interactions
may be controlled by the catalytic activity of LRRK2, either
towards itself or currently unknown substrates. If correct, not
only the catalytic activity of LRRK2, but also the modulation
of distinct protein interactions should be considered possible
targets for therapeutic strategies.
3. LRRK2 and the Regulation of Autophagy
The precise molecular mechanism(s) of LRRK2 function
remain unclear. Certain phenotypes are robustly seen, such
as the acutely toxic nature of pathogenic mutant forms
of LRRK2 upon high-level overexpression in cultured cells
[28–31]. Cell death is also evident upon viral vector-
mediated expression of mutant LRRK2 in vivo [32, 33], and
toxicity seems to depend on kinase activity [28, 29, 32]. In
neuronal cellular models where cell death is not apparent,
neurite shortening represents another consistent phenotype
associated with mutant LRRK2 expression [34–42]. Where
investigated, this also seems kinase activity-dependent and
mediated by macroautophagy [34, 35, 41, 42]. All mutations
tested to date have at least one of these eﬀects on cells.
Thus, the cellular pathway(s) underlying LRRK2 toxicity
may involve altered macroautophagy, which in neurons
may lead to neurite shortening and eventual cell demise.
If so, elucidating the mechanism(s) by which LRRK2 alters
macroautophagy becomes key.
Apart from playing an important role in determining
neurite length [43], macroautophagy (thereafter named
autophagy) has recently gained attention for its contribution
to the pathogenesis of several neurodegenerative diseases
including PD [44–46]. Autophagy is a process by which
cytosolic constituents, including damaged organelles and
aggregated proteins, are engulfed within specialized double-
membraned vesicles called autophagosomes. Autophago-
somes then fuse with amphisomes or lysosomes, followed
by the hydrolytic degradation of products in lysosomes
and reformation of these organelles to maintain cellular
degradative capacity [47, 48]. Disrupting any part of this
process impairs autophagic flux, accompanied by the accu-
mulation of autophagic substrates and organelles [47, 48]. In
addition, autophagy and endocytosis share lysosomes as their
common end-point [49], such that it has been very diﬃcult
to define whether LRRK2 plays positive or negative roles in
autophagic-lysosomal clearance.
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A wealth of studies indicate that LRRK2 regulates
autophagy. For example, various lines of knockout mice
have been generated, which display an increase in the
number and size of secondary lysosomes and autolysosome-
like structures in the kidney [50–52]. An accumulation of
lipofuscin granules, highly oxidized, and crosslinked proteins
and lipids which cannot be properly degraded, and p62, an
autophagy substrate, have also been observed [50–52]. Such
abnormal accumulation of undigested material indicates an
impairment in the autophagosomal-lysosomal degradation
system. To determine a possible defect along the autophagic
pathway, the levels of LC3I and LC3II have been analyzed.
LC3II, the lipidated form of LC3I, becomes bound to
the autophagosomal membrane and serves as a reliable
indicator of autophagic activity [53]. Studies analyzing the
levels of LC3II in the absence of LRRK2 in the kidney
indicate either no change [52], or a biphasic change with
an initial enhancement of flux at young age, followed by
an impairment of flux over time [50, 51]. This block in
flux has been interpreted to be due to an “overload” of
the system, resulting in impaired clearance and/or recycling
of autophagic components/autolysosomes [51]. Whilst an
interesting hypothesis, it depends on assigning a rate-
limiting step in the autophagy process, which will need
further proof.
In agreement with the in vivo data of young animals,
RNAi-mediated knockdown of LRRK2 has been found to
result in increased autophagic flux under starvation condi-
tions in a human embryonic kidney cell line (HEK293) [25].
Unfortunately, flux experiments were not performed under
nutrient-rich conditions in these knockdown cells. Con-
versely, overexpression of R1441C mutant LRRK2 caused a
block in autophagic flux, as evidenced by the accumulation of
multivesicular bodies and large autophagosomes containing
incompletely degraded material and increased levels of
p62 [25]. Similarly, in our studies overexpressing wildtype
and G2019S mutant LRRK2 in HEK293 cells, we found
improper autophagic-lysosomal clearance, as indicated by
an accumulation of autophagic structures and lipid droplets
[54, 55]. Thus, at least in the kidney and in kidney-derived
cell lines, the normal function of LRRK2 may be related to
negatively regulating autophagic clearance and/or lysosomal
homeostasis. Too much LRRK2 activity then would dampen,
whilst too little activity would enhance autophagic flux. If
the latter overloads the system with time, any deregulation of
LRRK2 activity may be damaging to the proper functioning
of the autophagic pathway in vivo.
4. Tissue-Specific versus Universal
Regulation of Autophagy
In contrast to kidney, there has been no evidence for the
accumulation of autophagic or lysosome-related structures
in the brains of aged mice lacking LRRK2 [50–52]. Thus,
LRRK2 may perform distinct roles in a tissue-specific man-
ner, with an eﬀect on autophagy in kidney, but not in brain.
Alternatively, LRRK1 may functionally compensate for the
loss of LRRK2 in the brain, but not in the kidney, the latter of
which contains small amounts of LRRK1 versus LRRK2 and
thus percentually suﬀers amuch bigger loss of LRRK proteins
[56, 57]. In addition, the homo- and heterodimerization of
LRRK1 and LRRK2 proteins has been reported [58, 59], with
LRRK1 involved in regulating endosomal traﬃcking [60, 61],
consistent with a role for both proteins in recycling and
degradation events. Generation of double-knockout lines
will be required to delineate whether a complete loss of
LRRK proteins in neurons results in age-related changes in
autophagy similar to those observed in the kidney.
As another possibility, the overall levels of LRRK proteins
present in diﬀerent tissues may predetermine whether a
phenotype is observed upon knockout versus overexpression
conditions. For example, as LRRK levels are very high in
kidney [56, 57], a knockout strategy may be more adequate
to uncover the (normal) role of LRRK2 in autophagic-
lysosomal clearance. Conversely, given the low levels of
LRRK2 in the brain, an overexpression approach, especially
of mutant, hyperactive LRRK2, may be more eﬀective.
Apart from diﬀerences in the levels of LRRK proteins,
the rate of basal autophagy also displays large diﬀerences
across distinct tissues. Thus, the same pathogenic mutation
of LRRK2 may give rise to diﬀerent degrees of pathology
depending on the cellular milieu in which it is operating [19].
As basal autophagy is very high in the kidney, a deregulation
may be more pronounced in this organ as compared to
other tissues. Nevertheless, if LRRK2 is a universal modulator
of autophagic/lysosomal clearance, changes should also be
detectable in other tissues such as brain, albeit possibly to
a lesser degree or in an age-dependent manner diﬃcult to
track using rodentmodels. In agreement with a universal role
in regulating autophagy, an overexpression approach using
G2019S mutant LRRK2 has been reported to cause abnormal
accumulation of autophagic and lysosomal structures in
primary cortical neurons and neuronal cell lines in culture
[34, 35]. Similarly, an accumulation of autophagic vacuoles,
including early and late autophagosomes, has been described
in the soma and processes in the cortex and striatum
from G2019S, and to a lesser degree R1441C, transgenic
mice with advanced age [40]. Thus, both in vitro and
in vivo, overexpression of mutant LRRK2 seems to cause
impaired autophagic-lysosomal clearance in neurons as
well. A decrease in autophagic flux, concomitant with an
increase in p62 levels, autophagosomes and lipid droplets
has recently also been described in human dopaminergic
neurons derived from induced pluripotent stem cells from
G2019S mutant LRRK2, but not control patients, after long-
term culture [42]. These data are important, as they indicate
that endogenous levels of mutant LRRK2 are suﬃcient to
induce an autophagic-lysosomal phenotype in dopaminergic
neurons with time. In contrast, fibroblasts from those same
patients do not reveal diﬀerences in autophagic clearance,
consistent with their extremely low levels of basal autophagic
activity [42]. However, the latter findings are in contrast to a
recent report suggesting elevated levels of autophagic activity
[62], and the precise role for mutant LRRK2 in autophagy
regulation in fibroblasts remains to be determined. Finally,
bone marrow-derived macrophages from mutant LRRK2
mice display a decrease in LC3II levels, possibly highlighting
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an autophagic phenotype in those cells as well [63]. All-
together, the currently available data indicate that LRRK2
can regulate autophagic-lysosomal clearance in neurons as
well as a variety of other cell types, possibly in a manner
dependent on the basal level of autophagy.
5. Mechanism of Autophagy Regulation
by LRRK2
If LRRK2 indeed regulates autophagic clearance, under-
standing the mechanism of action becomes important
to develop alternative and/or complementary treatment
strategies. The eﬀects of LRRK2 on autophagic-lysosomal
clearance may reflect its primary mechanism of action
or may occur secondarily, elicited as a response to some
upstream event(s). Even if direct, many distinct scenarios
remain possible, as autophagy intersects with both secretory
and endocytic pathways at several points [64]. Given its
heterodimerization with LRRK1 [58, 59], which has been
reported to regulate traﬃcking events of the epidermal
growth factor receptor (EGFR) between early and late
endosomes, endosome motility and sorting of the epidermal
growth factor receptor (EGFR) to the inner vesicles of mul-
tivesicular bodies [60, 61], one may speculate that LRRK2
regulates similar events, with consequences for autophagic
pathways involving multivesicular bodies [65].
Apart from this mere analogy, LRRK2 has been shown
to interact with the GTPase rab5b, a key regulator of
early endocytic vesicle traﬃcking [66]. Overexpression or
knockdown of LRRK2 cause a decrease in presynaptic vesicle
endocytosis rates, again indicating that both too much and
too little LRRK2 adversely alter the balance of homeostatic
mechanisms, in this case controlling endocytosis [66].
Similarly, both overexpression or knockdown of LRRK2
induce defects in vesicle endocytosis upon depolarization
of primary neuronal cultures [67, 68], which may involve
interactions of LRRK2 with a series of endocytic proteins
apart from rab5b [68], but further studies are needed to
determine how LRRK2 may regulate the function of any of
these proteins. Interestingly, rab5b, apart from regulating the
endocytic pathway [69] has recently been shown to play an
additional positive role in autophagy by regulating an early
step of autophagosome formation in a TORC1-independent
manner [70]. Thus, a LRRK2-mediated regulation of rab5b
may rather directly impact upon autophagic flux. Indirect
LRRK2-mediated regulation of autophagy via changes in
endocytosis can be envisioned as well, as endocytosis enables
the formation of distinct signal transduction complexes
which define specialized endosomal-lysosomal signaling
platforms [71]. LRRK2-mediated changes in endocytosis
maymodulate the formation of those intracellular complexes
to regulate signalling cascades including Wnt or MAP kinase
cascades [71], both of which have been shown to be aﬀected
by LRRK2 [18], and which then may modulate the function
of downstream autophagic components.
Multiple data support the idea that LRRK2 also modu-
lates late steps in the autophagic-lysosomal clearance path-
way. The fusion of both autophagosomes and endosomes
with lysosomes requires rab7, as does the process of lysosome
reformation [49, 72–74], and interfering with rab7 function
will thus aﬀect autophagic-lysosomal clearance. Indeed, at
least in Drosophila, the LRRK2 homolog seems to interact
with rab7 on late endosomes and lysosomes to negatively
regulate rab7-dependent perinuclear lysosomal positioning
required for the eﬃcient degradation of autophagosomes
[75]. Another recent study in C. elegans expressing human
wildtype or mutant LRRK2 in conjunction with proteostatic
stress indicates increased expression of numerous proteins
including a subunit of the V-type proton ATPase [76, 77],
and the behavioural motor deficits observed in these double-
transgenic worms can be reverted by increasing autophagic
flux using a rapamycin analog. These data are consistent with
our findings that mutant LRRK2 may increase lysosomal pH
and concomitantly decrease lysosomal clearance, a process
reverted by rapamycin, but not by other compounds which
increase autophagy in an mTOR-independent manner [54].
It remains to be seen whether the beneficial eﬀect of the
rapamycin analog on motor output is related to an mTOR-
dependent increase in degradative capacity as autophagic
flux is enhanced, a decrease in protein synthesis, an eﬀect
on lysosomal homeostasis, or a combination thereof. Taken
alltogether, a picture is emerging whereby LRRK2 may
regulate both early and late steps of autophagic-lysosomal
clearance in a rab protein-dependent manner (Figure 2).
6. A Link between LRRK2, Autophagy,
and NAADP-Mediated Endolysosomal
Calcium Signaling
In agreement with other reports, we also found an increase in
autophagosome numbers upon transient overexpression of
wildtype and G2019S-mutant, but not kinase-dead LRRK2
in various cell lines including dopaminergic neuroendocrine
cells [54, 55]. Interestingly, we found that these eﬀects were
inhibited by the calcium chelator BAPTA, suggesting that
they were calcium-dependent. The eﬀects of LRRK2 over-
expression on autophagosome numbers were also blocked
when genetically depleting ER calcium stores and were
accompanied by an increase in the pH of a population of
lysosomes and an increase in the number of lipid droplets.
This phenotype closelymatches the one triggered byNAADP,
which evokes cytosolic calcium signals that can be amplified
by ER calcium stores, causes partial alkalinization of acidic
stores, and induces lipid accumulation [78–80]. NAADP is
a potent agonist-generated second messenger and capable of
triggering complex calcium signals which are initiated from
acidic stores and are being subsequently amplified by ER
calcium release channels [81–83]. Targets for NAADP are
likely comprised of the endolysosomal two-pore channels
TPC1 and TPC2 [84–86], even though recent studies indicate
that NAADP does not directly bind to TPCs, but rather
indirectly through currently unidentified associated low-
molecular weight binding proteins [87]. In either case, there
is a growing appreciation of the importance of endolyso-
somal organelles as mobilizable calcium stores [81, 88],
and intraluminal calcium seems required for endolysosomal
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Figure 2: Possible mechanisms by which LRRK2may regulate events related to endolysosomal and autophagic function. Modulation of rab5
function could cause changes in endocytosis and/or autophagosome formation. Altered endocytosis could also modulate signalling events
occurring at the plasma membrane or on intracellular organelles, thereby, indirectly impacting upon autophagy through phosphorylation
events of distinct proteins required for the process. At later stages, through modulating rab7 function, LRRK2 may alter the fusion of
autophagosomes/endosomes with lysosomes or impair lysosome reformation, which would impact upon autophagic-lysosomal clearance
in both cases. As most of the abovementioned membrane fusion/reformation steps require intraluminal calcium, LRRK2 may further
regulate endolysosomal clearance by modulating NAADP-sensitive calcium channels (NAADP-R) located on endosomes and lysosomes.
The increasing intraluminal calcium concentrations along the endocytic/lysosomal pathway are indicated by the progressively darkened blue
color. Ligand binding to receptors, followed by endocytosis and interaction with signalling complexes are schematically indicated. EE: early
endosome; AV: autophagosome; LE/MVB: late endosome/multivesicular body; LYS: lysosome. For further details and references, see text.
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Figure 3: Diagram of proposedmechanism(s) by which LRRK2 regulates autophagy viamodulation of NAADP-dependent calcium channels
(NAADP-R) on lysosomes. LRRK2 localizes to lysosomes and regulates calcium release through two-pore channels (TPCs). Whether this
is due to a direct interaction of LRRK2 with NAADP-R, an indirect interaction via rab7 or additional proteins, or whether it is mediated
by a phosphorylation event remains to be determined. Calcium release from acidic organelles then causes calcium-induced calcium release
(CICR) from the ER to amplify cytosolic calcium signals, which leads to the activation of a cascade to increase autophagosome numbers.
Diminished luminal calcium will further cause a decrease in autophagosome-lysosome fusion, and increased pHmay have additional eﬀects
on eventually impairing lysosomal proteolysis, leading to the observed autophagic-lysosomal clearance phenotype.
membrane fusion events, thus, directly impacting upon
endosomal and autophagic traﬃcking events [73].
The analogy between the eﬀects of LRRK2 overexpres-
sion and NAADP action prompted us to test the connection
between NAADP and LRRK2 action. Accordingly, we
found that elevation of cellular NAADP levels using a cell
permeable NAADP analogue (NAADP-AM) [89] increases
autophagosome numbers, lysosomal pH, and lipid droplet
numbers, thus, largely mimicking the eﬀects observed
upon LRRK2 overexpression [54]. Conversely, the NAADP
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antagonist NED19 recently identified by virtual screening
methods [90] reverted the eﬀects of LRRK2. The increase in
autophagosome number could also be blocked by overex-
pression of TPC2 mutated within the pore region [91]. This
inactive mutant likely acts in a dominant manner similar
to TPC1 in which the corresponding residue is mutated
[84, 92]. Together, these data uncover a hitherto unknown
link between NAADP and LRRK2 function (Figure 3).
7. Summary
A wealth of recent data supports the idea that LRRK2
regulates autophagy. Another ROCO protein family member,
death-associated protein kinase 1 (DAPK1), also seems
to be an essential regulator of autophagy [93], and it
will be interesting to determine whether other ROCO
proteins are autophagy modulators as well. Furthermore,
LRRK2 variants have been associated with Crohn’s disease
(CD), an inflammatory bowel disease [94]. As other CD-
associated risk genes are also linked to autophagy trig-
gered as an antibacterial response, the disease may result
from ineﬀective control of bacterial infection and resultant
chronic inflammation [95]. Similarly, recent data suggest
that LRRK2 dysfunction in PD may involve the immune
system [96], and the involvement of aberrant autophagy
in such process warrants further investigation. Whilst the
link between LRRK2 and autophagy is becoming solid, the
precise underlying mechanism(s) remain unknown. Both
direct and indirect scenarios can be envisioned, and evidence
for both is emerging. Rab proteins and calcium seem
to play potentially important and not mutually exclusive
roles. Calcium is known to both positively and negatively
regulate autophagy, and these dual eﬀects may depend on
the precise intraorganellar location at which it is required
for autophagosome-lysosome or endosome-lysosome fusion,
respectively [49, 72]. Many questions remain to be addressed,
such as whether TPCs (or NAADP binding proteins) are
LRRK2 targets, whether LRRK2 causes indeed measurable
changes in intracellular calcium levels, or how LRRK2
regulates the activity or localization of distinct rab proteins.
Additional work is needed toward delineating the precise
molecular links between LRRK2, autophagy, and NAADP-
mediated events.
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